Source: Eur Respir Monogr 2021; 91: 353-372



Rating:

Share or cite this content

Citations should be made in the following way:
Mazharul Maishan, Wolfgang M. Kuebler, Diana L. Lim, Michael A. Matthay. Progress and potential of mesenchymal stromal cell therapy in acute respiratory distress syndrome. Eur Respir Monogr 2021; 91: 353-372

Member's Comments

No comment yet.

Related content which might interest you: Understanding the impact of the lung microenvironment to enhance the therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome Source: Eur Respir J, 58 (4) 2100986; 10.1183/13993003.00986-2021 Year: 2021 Combined cell therapy and anticoagulants for acute respiratory distress syndrome Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Effects of hypercapnic acidosis on the primary cells relevant to ARDS pathophysiology and the therapeutic potential of mesenchymal stem cells Source: International Congress 2017 – Anti-inflammatory and pro-repair mediators in acute lung injury Year: 2017 Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome Source: Eur Respir Rev, 29 (156) 200114; 10.1183/16000617.0114-2020 Year: 2020 Acute increase in KL-6/MUC1 mucin as a potential trigger of disseminated intravascular coagulation in acute respiratory distress syndrome Source: Annual Congress 2006 - Acute respiratory distress syndrome (ARDS): from pathophysiology to clinical management Year: 2006 Pathogenesis of acute microvascular lung injury and the acute respiratory distress syndrome Source: ISSN=1025-448x, ISBN=1-904097-23-5, page=22 Year: 2002 Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury Source: Eur Respir J 2009; 33: 1403-1414 Year: 2009 Overview of current lung imaging in acute respiratory distress syndrome Source: Eur Respir Rev 2014; 23: 519-530 Year: 2014 Early intervention with non-invasive respiratory therapies in mild acute respiratory distress syndrome secondary to COVID-19 Source: Virtual Congress 2021 – Non-invasive respiratory support in COVID-19 Year: 2021 Prognosis of acute respiratory distress syndrome in neutropenic cancer patients Source: Eur Respir J 2012; 40: 169-176 Year: 2012 Acute respiratory distress syndrome after renal transplantation Source: Annual Congress 2010 - Acute respiratory failure Year: 2010 Current invasive ventilatory strategies in acute respiratory distress syndrome Source: ISSN=1025-448x, ISBN=1-904097-23-5, page=161 Year: 2002 Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for severe acute respiratory syndrome coronavirus 2 patients Source: Eur Respir J, 56 (5) 2001531; 10.1183/13993003.01531-2020 Year: 2020 Surfactant therapy in acute lung injury/acute respiratory distress syndrome Source: Eur Respir Mon 2012; 55: 54-64 Year: 2012 Recurrent airway obstructions increase circulating mesenchymal stem cells in an acute rat model of sleep apnea Source: Annual Congress 2008 - Pathogenesis of obstructive sleep apnoea Year: 2008 Epidemiology and prognosis of acute respiratory distress syndrome Source: ISSN=1025-448x, ISBN=1-904097-23-5, page=1 Year: 2002 The impact of two partial ventilatory support modalities on lung histology and inflammatory mediators in a model of acute respiratory distress syndrome Source: Annual Congress 2007 - Acute lung injury and inflammation Year: 2007 Alveolar lymphocyte phenotype and respiratory distress syndrome Source: Annual Congress 2011 - Lung cell injury and repair Year: 2011 The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance Source: Eur Respir J 2014; 43: 276-285 Year: 2004 Neuregulin-1 as a potentially novel biomarker in acute respiratory distress syndrome Source: Eur Respir J 2013; 41: 259-261 Year: 2013